CLINICAL FEATURES, TREATMENT APPROACHES AND PROMISING CONTRIBUTIONS OF NANOMEDICINES TOWARDS COVID-19

The World Health Organization (WHO) declared COVID -19 a pandemic on March 11 2020.  As of today, there have been 122 million COVID -19-update cases worldwide, and the counting goes on. Unfortunately, strategic measures such as total lockdown, social and self-isolation, and gradual lifting of some of these restrictions both pose economic, social, and psychological distress and are thought to have affected people more than the virus itself. There is no specific antiviral drug available at this time. However, there are currently five main vaccines on the market that aim to protect the population from contracting the coronavirus. Moderna, Pfizer/BioNTech, Oxford/AstraZeneca, Sputnil V, and Sinopharm vaccines are among those included. Furthermore, developing an effective medication that is reliable for the treatment may be more effective, but it is more difficult.  To accomplish this, molecular bio-interaction, virulence, clinical, and pathological features of COVID -19 viruses must be clearly understood.  Additionally, the designation of potential antiviral drugs in the form of nanomedicines will optimize the therapeutic outcome and improve the quality of life. This study expanded on the clinical, pathological, and virulence features of COVID-19 and highlighted the need to investigate nanomedicines as a gold option that could potentiate the world to win the fight against COVID-19 infection.